Many dual catalytic mTOR inhibitors do not have tolerable clinical profiles, [14] so we investigated a clinically acceptable dual PI3K/mTOR inhibitor omipalisib (GSK2126458) [15] that has completed a Phase 1 clinical trial in patients with advanced solid tumors [16] and another Phase 1 trial in patients with idiopathic pulmonary fibrosis [17]. Here, MTOR is linked to pulmonary fibrosis.